Advancements in Antidiabetic Therapy: An extensive study on the use of Polypills to treat type 2 diabetes

Abstract

The hallmark of type 2 diabetes (T2DM) is elevated blood glucose levels brought on by insulin resistance or inadequate insulin synthesis. Oral hypoglycaemic medications and insulin therapy are two examples of pharmacological therapies used in conjunction with lifestyle changes like diet and exercise to manage type 2 diabetes. However, because T2DM is a complex disease and requires many drugs to regulate different risk factors, managing the condition can be difficult. Polypills, or cardiovascular fixed-dose combination pills, have the potential to alleviate the pervasive inaccessibility and noncompliance with established medications. Switching from existing individually taken drugs is usually required to begin polypill-based therapy. The impact of polypill treatment across various patterns of previous pharmaceutical regimen is of relevance due to the heterogeneity in usual care. Utilizing a polypill helps streamline drug schedules, lessening patients' burden with pills, and possibly increasing adherence. In type 2 diabetes, when controlling blood pressure, cholesterol, and blood glucose levels frequently necessitates the use of many drugs, this is especially crucial. Recommendations state that those with established cardiovascular disease are probably now receiving aspirin, a statin, and blood pressure (BP)-lowering drugs. It might be reasonable to combine these medications into a cardiovascular polypill for these patients in order to reduce prescription gaps and non-adherence. A sizable portion of individuals suffering from long-term cardiovascular conditions currently use a combination of prescription drugs. Introduce a polypill to high-risk patients to reduce prescription gaps and enhance adherence to recommended therapy